Delirium, Dementia, Amnestic, Cognitive Disorders  >>  begacestat (GSI-953)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
begacestat (GSI-953) / Pfizer
NCT00479219: Study Evaluating GSI-953 in Healthy Young and Alzheimer's Patients

Completed
1
17
US
GSI-953, Placebo
Wyeth is now a wholly owned subsidiary of Pfizer
Alzheimer Disease
10/07
10/07

Download Options